vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.
UNIVERSAL TECHNICAL INSTITUTE INC is the larger business by last-quarter revenue ($220.8M vs $139.2M, roughly 1.6× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 5.8%, a 29.7% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 9.6%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-19.2M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 9.5%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.
ADMA vs UTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $220.8M |
| Net Profit | $49.4M | $12.8M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 7.1% |
| Net Margin | 35.5% | 5.8% |
| Revenue YoY | 18.4% | 9.6% |
| Net Profit YoY | -55.9% | -42.1% |
| EPS (diluted) | $0.20 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $220.8M | ||
| Q3 25 | $134.2M | $222.4M | ||
| Q2 25 | $122.0M | $204.3M | ||
| Q1 25 | $114.8M | $207.4M | ||
| Q4 24 | $117.5M | $201.4M | ||
| Q3 24 | $119.8M | $196.4M | ||
| Q2 24 | $107.2M | $177.5M | ||
| Q1 24 | $81.9M | $184.2M |
| Q4 25 | $49.4M | $12.8M | ||
| Q3 25 | $36.4M | $18.8M | ||
| Q2 25 | $34.2M | $10.7M | ||
| Q1 25 | $26.9M | $11.4M | ||
| Q4 24 | $111.9M | $22.2M | ||
| Q3 24 | $35.9M | $18.8M | ||
| Q2 24 | $32.1M | $5.0M | ||
| Q1 24 | $17.8M | $7.8M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 7.1% | ||
| Q3 25 | 38.0% | 11.2% | ||
| Q2 25 | 35.1% | 6.9% | ||
| Q1 25 | 30.4% | 8.1% | ||
| Q4 24 | 32.6% | 13.6% | ||
| Q3 24 | 33.1% | 13.3% | ||
| Q2 24 | 36.6% | 4.2% | ||
| Q1 24 | 26.7% | 6.1% |
| Q4 25 | 35.5% | 5.8% | ||
| Q3 25 | 27.1% | 8.4% | ||
| Q2 25 | 28.1% | 5.2% | ||
| Q1 25 | 23.4% | 5.5% | ||
| Q4 24 | 95.2% | 11.0% | ||
| Q3 24 | 30.0% | 9.6% | ||
| Q2 24 | 29.9% | 2.8% | ||
| Q1 24 | 21.7% | 4.2% |
| Q4 25 | $0.20 | $0.23 | ||
| Q3 25 | $0.15 | $0.33 | ||
| Q2 25 | $0.14 | $0.19 | ||
| Q1 25 | $0.11 | $0.21 | ||
| Q4 24 | $0.45 | $0.40 | ||
| Q3 24 | $0.15 | $0.35 | ||
| Q2 24 | $0.13 | $0.09 | ||
| Q1 24 | $0.08 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $162.8M |
| Total DebtLower is stronger | $72.1M | $101.4M |
| Stockholders' EquityBook value | $477.3M | $335.9M |
| Total Assets | $624.2M | $834.0M |
| Debt / EquityLower = less leverage | 0.15× | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $162.8M | ||
| Q3 25 | $61.4M | $169.1M | ||
| Q2 25 | $90.3M | $70.7M | ||
| Q1 25 | $71.6M | $96.0M | ||
| Q4 24 | $103.1M | $172.0M | ||
| Q3 24 | $86.7M | $161.9M | ||
| Q2 24 | $88.2M | $115.5M | ||
| Q1 24 | $45.3M | $116.1M |
| Q4 25 | $72.1M | $101.4M | ||
| Q3 25 | $72.4M | $87.1M | ||
| Q2 25 | — | $73.8M | ||
| Q1 25 | — | $94.4M | ||
| Q4 24 | $72.3M | $120.1M | ||
| Q3 24 | — | $125.7M | ||
| Q2 24 | — | $137.3M | ||
| Q1 24 | — | $141.9M |
| Q4 25 | $477.3M | $335.9M | ||
| Q3 25 | $431.2M | $328.1M | ||
| Q2 25 | $398.3M | $306.8M | ||
| Q1 25 | $373.4M | $293.9M | ||
| Q4 24 | $349.0M | $280.0M | ||
| Q3 24 | $231.9M | $260.2M | ||
| Q2 24 | $188.3M | $239.4M | ||
| Q1 24 | $153.7M | $232.6M |
| Q4 25 | $624.2M | $834.0M | ||
| Q3 25 | $568.7M | $826.1M | ||
| Q2 25 | $558.4M | $740.8M | ||
| Q1 25 | $510.6M | $720.4M | ||
| Q4 24 | $488.7M | $753.8M | ||
| Q3 24 | $390.6M | $744.6M | ||
| Q2 24 | $376.4M | $706.0M | ||
| Q1 24 | $350.9M | $702.1M |
| Q4 25 | 0.15× | 0.30× | ||
| Q3 25 | 0.17× | 0.27× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | 0.21× | 0.43× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.57× | ||
| Q1 24 | — | 0.61× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $3.1M |
| Free Cash FlowOCF − Capex | $34.6M | $-19.2M |
| FCF MarginFCF / Revenue | 24.8% | -8.7% |
| Capex IntensityCapex / Revenue | 0.8% | 10.1% |
| Cash ConversionOCF / Net Profit | 0.72× | 0.24× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $16.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $3.1M | ||
| Q3 25 | $13.3M | $57.1M | ||
| Q2 25 | $21.1M | $18.1M | ||
| Q1 25 | $-19.7M | $-789.0K | ||
| Q4 24 | $50.2M | $23.0M | ||
| Q3 24 | $25.0M | $67.5M | ||
| Q2 24 | $45.6M | $10.0M | ||
| Q1 24 | $-2.2M | $-2.5M |
| Q4 25 | $34.6M | $-19.2M | ||
| Q3 25 | $-1.1M | $40.6M | ||
| Q2 25 | $18.7M | $6.8M | ||
| Q1 25 | $-24.4M | $-11.7M | ||
| Q4 24 | $47.5M | $19.6M | ||
| Q3 24 | $24.0M | $60.0M | ||
| Q2 24 | $43.6M | $3.0M | ||
| Q1 24 | $-4.6M | $-8.4M |
| Q4 25 | 24.8% | -8.7% | ||
| Q3 25 | -0.8% | 18.3% | ||
| Q2 25 | 15.3% | 3.4% | ||
| Q1 25 | -21.2% | -5.7% | ||
| Q4 24 | 40.4% | 9.7% | ||
| Q3 24 | 20.0% | 30.6% | ||
| Q2 24 | 40.7% | 1.7% | ||
| Q1 24 | -5.6% | -4.6% |
| Q4 25 | 0.8% | 10.1% | ||
| Q3 25 | 10.7% | 7.4% | ||
| Q2 25 | 2.0% | 5.5% | ||
| Q1 25 | 4.1% | 5.3% | ||
| Q4 24 | 2.3% | 1.7% | ||
| Q3 24 | 0.9% | 3.8% | ||
| Q2 24 | 1.9% | 4.0% | ||
| Q1 24 | 2.9% | 3.2% |
| Q4 25 | 0.72× | 0.24× | ||
| Q3 25 | 0.36× | 3.04× | ||
| Q2 25 | 0.62× | 1.69× | ||
| Q1 25 | -0.73× | -0.07× | ||
| Q4 24 | 0.45× | 1.04× | ||
| Q3 24 | 0.70× | 3.58× | ||
| Q2 24 | 1.42× | 2.01× | ||
| Q1 24 | -0.12× | -0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
UTI
| UTI | $142.8M | 65% |
| Concorde | $78.0M | 35% |
